Ankylosing Spondylitis - Ankylosing Spondylitis - MSD Manual Professional Edition (2024)

1. 1. Khan MA, Braun WE, Kushner I, et al: HLA B27 in Ankylosing Spondylitis: Differences in Frequency and Relative Risk in American Blacks and Caucasians.J Rheumatol. 2023;50(1):39-43.

Most patients have predominantly axial involvement (called axial ankylosing spondylitis). Some have predominately peripheral involvement. Among those with axial involvement, some have no evidence of sacroiliitis on radiographs. Thus, some experts have classified ankylosing spondylitis as follows:

• Axial ankylosing spondylitis: Has predominantly axial involvement and findings typical of bilateral sacroiliitis on imaging

• Nonradiographic ankylosing spondylitis: Clinically similar to axial ankylosing spondylitis but without findings typical of sacroiliitis on imaging

• Peripheral ankylosing spondylitis: Ankylosing spondylitis with predominantly peripheral joint involvement

The most frequent manifestation of ankylosing spondylitis is inflammatory back pain, but disease can begin in peripheral joints, especially in children and women, and rarely with acute iridocycl*tis (iritis, anterior uveitis). Other early symptoms and signs are diminished chest expansion from diffuse costovertebral involvement, and occasionally fatigue, anorexia, weight loss, and anemia.

Back pain—often nocturnal and of varying intensity—eventually becomes recurrent. Morning stiffness, typically relieved by activity, and paraspinal muscle spasm develop. A flexed or bent-over posture eases back pain and paraspinal muscle spasm; thus, kyphosis is common in untreated patients. Severe hip and shoulder arthritis can eventually develop. In late stages, untreated patients may develop accentuated kyphosis, loss of lumbar lordosis, and fixed bent-forward posturing, with compromised pulmonary function and an inability to lie flat. There may be peripheral potentially deforming joint involvement, sometimes involving isolated digit diffuse swelling (dactylitis). Achilles and patellar tendinitis can occur.

Systemic manifestations of ankylosing spondylitis occur in approximately 25% of patients (1). Recurrent, acute anterior uveitis is common; less commonly it becomes protracted and severe enough to impair vision. Neurologic signs occasionally result from compression radiculitis or sciatica, vertebral fracture or subluxation, or cauda equina syndrome. Cardiovascular manifestations include aortic insufficiency, aortitis, angina, pericarditis, and cardiac conduction abnormalities (which may be asymptomatic). Dyspnea, cough, or hemoptysis can rarely result from nontuberculous fibrosis or cavitation of an upper lobe of the lung; cavitary lesions can become secondarily infected with Aspergillus. Nonspecific colitis has been noted in 30% of patients with ankylosing spondylitis. Subcutaneous nodules, like those in patients with rheumatoid arthritis, do not develop in patients with ankylosing spondylitis.

• Lumbosacral spine and sacroiliac joint radiography

• Blood tests (erythrocyte sedimentation rate, C-reactive protein, human leukocyte antigen B27 [HLA-B27], and complete blood count) or explicit clinical criteria (Assessment of SpondyloArthritis international Society criteria)

• Pelvic/spine MRI in select patients

Ankylosing spondylitis should be suspected in patients, particularly young men, with nocturnal back pain plus prolonged morning stiffness and kyphosis, diminished chest expansion, Achilles or patellar tendinitis, or unexplained anterior uveitis. A first-degree relative with ankylosing spondylitis should raise suspicion.

Patients should generally be tested with erythrocyte sedimentation rate, C-reactive protein, and complete blood count. Rheumatoid factor (RF), anti-anticyclic citrullinated peptide [CCP] antibodies, and antinuclear antibodies are needed only if peripheral arthritis suggests other diagnoses. The HLA-B27 allele is present in 90% of White patients with ankylosing spondylitis, but it is also present in up to 10% of the general population depending on ethnicity (1). No laboratory test is diagnostic, but results can increase suspicion for the disorder or rule out other disorders that can simulate ankylosing spondylitis. If, after these tests, ankylosing spondylitis is still suspected, patients should undergo radiography or MRI of the lumbosacral spine and sacroiliac joints; demonstration of sacroiliitis on radiograph strongly supports the diagnosis.

Some patients should undergo pelvic MRI to look for sacroiliitis that is not seen on radiographs. In these patients, MRI shows osteitis or early erosions.

Although there are several existing diagnostic criteria for patients with suspected ankylosing spondylitis, the Assessment of SpondyloArthritis international Society (ASAS) criteria (2, 3, 4) are most often applied. They are useful in diagnosing patients earlier in the disease process, particularly those without spondyloarthritis on imaging. The ASAS criteria for axial spondyloarthritis are applied to patients who have had back pain for > 3 months and who are < 45 years of age at onset.

Diagnosis can be done using ASAS imaging or clinical criteria. To fulfill the imaging criteria, patients must have radiographic or MRI evidence of sacroiliitis plus at least 1 spondyloarthritis feature. To fulfill the clinical criteria, patients must have HLA-B27 plus at least 2 separate spondyloarthritis features. ASAS spondyloarthritis features include the following:

• Dactylitis

• Enthesitis of the heel

• Family history of spondyloarthritis

• History of inflammatory back pain

• Arthritis

• Psoriasis

• Inflammatory bowel disease

• Presence of HLA-B27

• Uveitis

• Elevated C-reactive protein

• Good response to nonsteroidal anti-inflammatory drugs

Historical features that distinguish inflammatory back pain from noninflammatory back pain include onset at ≤ 40 years, gradual onset, morning stiffness, improvement with activity, and duration of symptoms ≥ 3 months before seeking medical attention.

Erythrocyte sedimentation rate and other acute-phase reactants (eg, C-reactive protein) are inconsistently elevated in patients with active ankylosing spondylitis. Tests for RF and antinuclear antibodies are negative. The HLA-B27 genetic marker is minimally helpful because positive and negative predictive values are low.

The earliest abnormalities on radiographs are pseudo-widening caused by subchondral erosions, followed by sclerosis or later narrowing and eventually fusion in the sacroiliac joints. Changes are symmetric. Early changes in the spine are upper lumbar vertebral squaring with sclerosis at the corners (shiny corner sign), spotty ligamentous calcification, and 1 or 2 evolving syndesmophytes. Late changes result in a “bamboo spine” appearance, resulting from prominent syndesmophytes, diffuse paraspinal ligamentous calcification, and osteoporosis; these changes develop in some patients on average over 10 years.

Changes typical of ankylosing spondylitis may not become visible on radiographs for years. MRI shows changes earlier, but there is no consensus regarding its role in routine diagnosis given the lack of prospective, validated data in regard to its diagnostic utility. Pelvic MRI should be done if the index of suspicion of spondyloarthritis is high or if there is a need to rule out other causes of the patient's symptoms. MRI shows early inflammatory changes, bone marrow edema on T2-weighted images with fatty changes, and subtle structural abnormalities. Lastly, routine monitoring of radiographic changes with serial spine radiographs is not recommended.

• Nonsteroidal anti-inflammatory drugs (NSAIDs)

• Exercises and supportive measures

The goals of treatment are relieving pain, maintaining joint range of motion, and preventing end-organ damage. Because the condition may cause lung fibrosis, cigarette smoking is discouraged. (See also ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.)

NSAIDs are first-line therapy for most patients. They reduce pain and suppress joint inflammation and muscle spasm, thereby increasing range of motion, which facilitates exercise and prevents contractures. Most NSAIDs work in ankylosing spondylitis, and tolerance and toxicity dictate drug choice. The daily dose of NSAIDs should be as low as possible, but maximum doses may be needed with active disease. Medication withdrawal should be attempted only slowly, after systemic and joint signs of active disease have been suppressed for several months.

Candida, diarrhea, herpes zoster, and worsening symptoms of inflammatory bowel disease.

Tapering of therapy rather than discontinuation can be considered in patients with sustained remission.

For proper posture and joint motion, daily exercise and other supportive measures (eg, postural training, therapeutic exercise) are vital to strengthen muscle groups that oppose the direction of potential deformities (ie, the extensor rather than flexor muscles). Reading while lying prone and pushing up on the elbows or pillows and thus extending the back may help keep the back flexible. Because chest wall motion can be restricted, which impairs lung function, cigarette smoking, which also impairs lung function, is strongly discouraged.

Intra-articular depot corticosteroids may be beneficial, particularly when 1 or 2 peripheral joints are more severely inflamed than others, thereby compromising exercise and rehabilitation. Imaging-guided corticosteroid injections (eg, with fluoroscopy or ultrasound) into the sacroiliac joints may occasionally help severe sacroiliitis.

For acute anterior uveitis

If severe hip arthritis develops, total hip arthroplasty may lessen pain and improve flexibility dramatically; although there may be a small but increased incidence of postoperative heterotopic ossification after joint replacement.

Ankylosing spondylitis is characterized by mild or moderate flares of active inflammation alternating with periods of little or no inflammation. Proper treatment in most patients results in minimal or no disability and in a full, productive life despite back stiffness. Occasionally, the course is severe and progressive, resulting in pronounced incapacitating deformities.

Poor prognostic factors include persistently high erythrocyte sedimentation rate and C-reactive protein, hip involvement, poor response to NSAIDs, presence of anterior uveitis, or heart or pulmonary disease.

• Ankylosing spondylitis is a systemic disorder that affects axial and peripheral joints and can cause constitutional symptoms, cardiac symptoms, and anterior uveitis (iritis).

• Initial manifestation is usually inflammatory back pain and stiffness sometimes along with peripheral joint symptoms and/or anterior uveitis.

• Diagnose based on the results of lumbosacral spine imaging, sacroiliac joint imaging, pelvic MRI, blood tests (erythrocyte sedimentation rate, C-reactive protein, and complete blood count), and/or explicit clinical criteria.

• Use nonsteroidal anti-inflammatory drugs to help reduce symptom severity and improve function.

• Use tumor necrosis factor (TNF) inhibitors, interleukin-17 (IL-17) inhibitors, or Janus kinase (JAK) inhibitors in patients who respond inadequately to NSAIDs.

The following English-language resource may be useful. Please note that THE MANUAL is not responsible for the content of this resource.

1. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update